Titan Bio-Tech [TITANBIO] vs Biocon [BIOCON] Detailed Stock Comparison
Titan Bio-Tech
BSE
Loading...
Biocon
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Titan Bio-Tech wins in 11 metrics, Biocon wins in 8 metrics, with 0 ties. Titan Bio-Tech appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Titan Bio-Tech | Biocon | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.96 | 43.00 | Titan Bio-Tech |
| Price-to-Book Ratio | 2.38 | 2.02 | Biocon |
| Debt-to-Equity Ratio | 1.82 | 66.26 | Titan Bio-Tech |
| PEG Ratio | N/A | 36.71 | N/A |
| EV/EBITDA | 14.26 | 20.18 | Titan Bio-Tech |
| Profit Margin (TTM) | 13.76% | 6.64% | Titan Bio-Tech |
| Operating Margin (TTM) | 10.60% | 15.98% | Biocon |
| EBITDA Margin (TTM) | 10.60% | 15.98% | Biocon |
| Return on Equity | 15.01% | 5.40% | Titan Bio-Tech |
| Return on Assets (TTM) | 8.02% | 1.68% | Titan Bio-Tech |
| Free Cash Flow (TTM) | $106.79M | $17.18B | Biocon |
| Dividend Yield | 0.47% | 0.26% | Titan Bio-Tech |
| 1-Year Return | -27.01% | 8.09% | Biocon |
| Price-to-Sales Ratio (TTM) | 2.34 | 3.19 | Titan Bio-Tech |
| Enterprise Value | $3.63B | $630.44B | Biocon |
| EV/Revenue Ratio | 2.32 | 4.13 | Titan Bio-Tech |
| Gross Profit Margin (TTM) | 57.31% | 66.20% | Biocon |
| Revenue per Share (TTM) | $189 | $127 | Titan Bio-Tech |
| Earnings per Share (Diluted) | $26.08 | $8.47 | Titan Bio-Tech |
| Beta (Stock Volatility) | 0.32 | 0.23 | Biocon |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Titan Bio-Tech vs Biocon Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Titan Bio-Tech | -4.67% | 4.49% | -3.34% | 0.20% | -38.24% | -42.03% |
| Biocon | -6.40% | -10.79% | -7.47% | 2.14% | -9.39% | -7.33% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Titan Bio-Tech | -27.01% | 89.08% | 205.28% | 1,425.34% | 1,669.40% | 1,991.49% |
| Biocon | 8.09% | 17.05% | -7.82% | 365.55% | 537.49% | 898.63% |
Performance & Financial Health Analysis: Titan Bio-Tech vs Biocon
| Metric | TITANBIO | BIOCON |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.66B | ₹486.32B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 9,704 | 4,140,709 |
| 90 Day Avg. Volume | 8,360 | 4,738,065 |
| Last Close | ₹442.35 | ₹341.75 |
| 52 Week Range | ₹373.65 - ₹1,017.85 | ₹291.00 - ₹406.00 |
| % from 52W High | -56.54% | -15.83% |
| All-Time High | ₹1,017.85 (Oct 21, 2024) | ₹487.75 (Dec 21, 2020) |
| % from All-Time High | -56.54% | -29.93% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.12% | 0.13% |
| Quarterly Earnings Growth | -0.19% | 1.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.07% |
| Operating Margin (TTM) | 0.11% | 0.16% |
| Return on Equity (TTM) | 0.15% | 0.05% |
| Debt to Equity (MRQ) | 1.82 | 66.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹185.75 | ₹180.66 |
| Cash per Share (MRQ) | ₹6.73 | ₹38.10 |
| Operating Cash Flow (TTM) | ₹201.23M | ₹40.61B |
| Levered Free Cash Flow (TTM) | ₹67.81M | ₹-28,161,748,992 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.47% | 0.26% |
| Last 12-Month Dividend | ₹2.00 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Titan Bio-Tech vs Biocon
| Metric | TITANBIO | BIOCON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.96 | 43.00 |
| Forward P/E | N/A | 36.71 |
| PEG Ratio | N/A | 36.71 |
| Price to Sales (TTM) | 2.34 | 3.19 |
| Price to Book (MRQ) | 2.38 | 2.02 |
| Market Capitalization | ||
| Market Capitalization | ₹3.66B | ₹486.32B |
| Enterprise Value | ₹3.63B | ₹630.44B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.32 | 4.13 |
| Enterprise to EBITDA | 14.26 | 20.18 |
| Risk & Other Metrics | ||
| Beta | 0.32 | 0.23 |
| Book Value per Share (MRQ) | ₹185.75 | ₹180.66 |
Financial Statements Comparison: Titan Bio-Tech vs Biocon
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TITANBIO | BIOCON |
|---|---|---|
| Revenue/Sales | ₹351.69M | ₹43.58B |
| Cost of Goods Sold | ₹150.13M | ₹14.73B |
| Gross Profit | ₹201.57M | ₹28.85B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹37.27M | ₹6.05B |
| EBITDA | ₹59.51M | ₹11.15B |
| Pre-Tax Income | ₹50.29M | ₹4.87B |
| Income Tax | ₹12.62M | ₹274.00M |
| Net Income (Profit) | ₹40.47M | ₹4.59B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TITANBIO | BIOCON |
|---|---|---|
| Cash & Equivalents | ₹51.28M | ₹32.27B |
| Total Current Assets | ₹790.38M | ₹162.86B |
| Total Current Liabilities | ₹177.36M | ₹143.34B |
| Long-Term Debt | ₹4.19M | ₹129.45B |
| Total Shareholders Equity | ₹1.53B | ₹277.13B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹571.62M | ₹93.12B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TITANBIO | BIOCON |
|---|---|---|
| Operating Cash Flow | ₹45.62M | N/A |
| Capital Expenditures | ₹-33.58M | N/A |
| Free Cash Flow | ₹12.24M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TITANBIO | BIOCON |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 9,704 | 4,140,709 |
| Average Daily Volume (90 Day) | 8,360 | 4,738,065 |
| Shares Outstanding | 8.26M | 1.20B |
| Float Shares | 2.64M | 523.49M |
| % Held by Insiders | 0.67% | 0.56% |
| % Held by Institutions | 0.00% | 0.23% |
Dividend Analysis & Yield Comparison: Titan Bio-Tech vs Biocon
| Metric | TITANBIO | BIOCON |
|---|---|---|
| Last 12-Month Dividend | ₹2.00 | ₹1.00 |
| Last 12-Month Dividend Yield | 0.47% | 0.26% |
| 3-Year Avg Annual Dividend | ₹1.77 | ₹1.33 |
| 3-Year Avg Dividend Yield | 0.45% | 0.36% |
| 3-Year Total Dividends | ₹5.30 | ₹4.00 |
| Ex-Dividend Date | Sep 23, 2024 | Jul 04, 2025 |